Sutro Biopharma (NASDAQ:STRO) Raised to “Sell” at Wall Street Zen

Posted by Stanley Muller on Oct 31st, 2026

Sutro Biopharma (NASDAQ:STRO – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

STRO has been the topic of several other research reports. Stifel Nicolaus set a $48.00 price target on shares of Sutro Biopharma and gave the company a “buy” rating in a report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research note on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of Sutro Biopharma in a research report on Friday, October 16th. Citizens Jmp reduced their target price on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 13th. Finally, Wedbush reiterated an “outperform” rating and set a $60.00 target price on shares of Sutro Biopharma in a report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sutro Biopharma currently has a consensus rating of “Buy” and a consensus price target of $49.50.

Check Out Our Latest Stock Report on STRO

Sutro Biopharma Stock Performance

Shares of STRO stock opened at $9.10 on Friday. The stock has a fifty day moving average price of $15.39 and a 200 day moving average price of $22.77. The stock has a market cap of $150.88 million, a PE ratio of -0.76 and a beta of 1.49. Sutro Biopharma has a 1 year low of $7.15 and a 1 year high of $43.85.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The firm had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. As a group, equities research analysts predict that Sutro Biopharma will post -8.41 earnings per share for the current year.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in shares of Sutro Biopharma in the second quarter worth approximately $359,000. Sigma Planning Corp bought a new position in Sutro Biopharma during the first quarter valued at approximately $312,000. Bank of America Corp DE lifted its position in Sutro Biopharma by 348.1% during the first quarter. Bank of America Corp DE now owns 18,873 shares of the company’s stock valued at $470,000 after purchasing an additional 14,661 shares during the period. Stempoint Capital LP purchased a new stake in Sutro Biopharma in the first quarter worth approximately $580,000. Finally, Bank of New York Mellon Corp purchased a new stake in Sutro Biopharma in the second quarter worth approximately $1,373,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.